Viridian Historical Balance Sheet

VRDN Stock

USD 21.87 0.04 0.18%

Trend analysis of Viridian Therapeutics balance sheet accounts such as Total Assets of 514.9 M, Short Long Term Debt Total of 22.1 M, Other Current Liabilities of 24.4 M or Total Current Liabilities of 28 M provides information on Viridian Therapeutics' total assets, liabilities, and equity, which is the actual value of Viridian Therapeutics to its prevalent stockholders. By breaking down trends over time using Viridian Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Viridian Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Viridian Therapeutics is a good buy for the upcoming year.

Viridian Therapeutics Inventory

(5.66 Million)

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.

About Viridian Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Viridian Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Viridian Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Viridian Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Viridian currently owns. An asset can also be divided into two categories, current and non-current.

Viridian Therapeutics Balance Sheet Chart

At this time, Viridian Therapeutics' Cash is very stable compared to the past year. As of the 29th of November 2024, Non Currrent Assets Other is likely to grow to about 1 M, while Current Deferred Revenue is likely to drop about 246.2 K.

Short Long Term Debt Total Other Current Liab Total Current Liabilities Inventory

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Viridian Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Viridian Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Viridian Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Viridian Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.At this time, Viridian Therapeutics' Cash is very stable compared to the past year. As of the 29th of November 2024, Non Currrent Assets Other is likely to grow to about 1 M, while Current Deferred Revenue is likely to drop about 246.2 K.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	520K	5.3M	21.0M	22.1M
Total Assets	203.7M	435.1M	490.4M	514.9M

Short Long Term Debt Total Total Assets

Viridian Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock Total Equity	Common Stock
Total Assets		0.25	0.99	0.66	1.0	0.94	-0.4	-0.87	-0.98	0.61	0.93	0.69	0.57	1.0	-0.61	0.98	0.83	-0.59	0.96	0.99	0.85	0.93	1.0	-0.38	0.83	0.86
Short Long Term Debt Total	0.25		0.23	0.7	0.2	0.32	-0.12	0.11	-0.24	-0.11	0.11	-0.09	-0.17	0.25	0.15	0.34	0.46	0.06	0.3	0.26	0.71	0.17	0.25	0.7	0.21	0.28
Other Current Liab	0.99	0.23		0.63	0.99	0.93	-0.46	-0.84	-0.98	0.54	0.89	0.65	0.52	0.99	-0.55	0.97	0.8	-0.57	0.93	0.97	0.82	0.91	0.99	-0.38	0.76	0.8
Total Current Liabilities	0.66	0.7	0.63		0.63	0.71	-0.45	-0.45	-0.61	0.53	0.6	0.59	0.51	0.66	-0.2	0.67	0.45	-0.2	0.57	0.63	0.9	0.68	0.66	0.42	0.44	0.47
Total Stockholder Equity	1.0	0.2	0.99	0.63		0.94	-0.4	-0.88	-0.98	0.61	0.93	0.7	0.58	1.0	-0.63	0.98	0.82	-0.6	0.95	0.99	0.82	0.93	1.0	-0.42	0.83	0.85
Property Plant And Equipment Net	0.94	0.32	0.93	0.71	0.94		-0.57	-0.73	-0.89	0.56	0.81	0.68	0.54	0.94	-0.48	0.96	0.74	-0.35	0.85	0.93	0.84	0.96	0.94	-0.23	0.71	0.75
Current Deferred Revenue	-0.4	-0.12	-0.46	-0.45	-0.4	-0.57		0.21	0.34	-0.23	-0.24	-0.42	-0.36	-0.4	-0.08	-0.39	-0.05	-0.23	-0.17	-0.33	-0.33	-0.51	-0.39	-0.12	0.14	0.04
Net Debt	-0.87	0.11	-0.84	-0.45	-0.88	-0.73	0.21		0.82	-0.84	-0.98	-0.84	-0.8	-0.87	0.62	-0.79	-0.6	0.71	-0.83	-0.84	-0.6	-0.8	-0.86	0.57	-0.78	-0.77
Retained Earnings	-0.98	-0.24	-0.98	-0.61	-0.98	-0.89	0.34	0.82		-0.5	-0.88	-0.59	-0.45	-0.98	0.65	-0.96	-0.84	0.67	-0.96	-0.99	-0.82	-0.88	-0.98	0.4	-0.84	-0.87
Accounts Payable	0.61	-0.11	0.54	0.53	0.61	0.56	-0.23	-0.84	-0.5		0.8	0.97	0.98	0.61	-0.4	0.53	0.22	-0.42	0.51	0.55	0.47	0.67	0.6	-0.26	0.51	0.48
Cash	0.93	0.11	0.89	0.6	0.93	0.81	-0.24	-0.98	-0.88	0.8		0.81	0.75	0.93	-0.59	0.87	0.72	-0.7	0.9	0.9	0.76	0.84	0.93	-0.43	0.83	0.83
Non Current Assets Total	0.69	-0.09	0.65	0.59	0.7	0.68	-0.42	-0.84	-0.59	0.97	0.81		0.97	0.69	-0.41	0.62	0.26	-0.36	0.55	0.63	0.53	0.79	0.69	-0.26	0.49	0.47
Non Currrent Assets Other	0.57	-0.17	0.52	0.51	0.58	0.54	-0.36	-0.8	-0.45	0.98	0.75	0.97		0.57	-0.33	0.48	0.13	-0.34	0.43	0.5	0.41	0.66	0.56	-0.24	0.39	0.36
Cash And Short Term Investments	1.0	0.25	0.99	0.66	1.0	0.94	-0.4	-0.87	-0.98	0.61	0.93	0.69	0.57		-0.61	0.98	0.82	-0.59	0.96	0.99	0.85	0.93	1.0	-0.38	0.83	0.86
Net Receivables	-0.61	0.15	-0.55	-0.2	-0.63	-0.48	-0.08	0.62	0.65	-0.4	-0.59	-0.41	-0.33	-0.61		-0.58	-0.47	0.59	-0.63	-0.66	-0.36	-0.52	-0.61	0.57	-0.74	-0.7
Common Stock Shares Outstanding	0.98	0.34	0.97	0.67	0.98	0.96	-0.39	-0.79	-0.96	0.53	0.87	0.62	0.48	0.98	-0.58		0.86	-0.49	0.96	0.99	0.87	0.91	0.98	-0.32	0.83	0.86
Non Current Liabilities Total	0.83	0.46	0.8	0.45	0.82	0.74	-0.05	-0.6	-0.84	0.22	0.72	0.26	0.13	0.82	-0.47	0.86		-0.57	0.93	0.86	0.79	0.64	0.83	-0.31	0.86	0.89
Inventory	-0.59	0.06	-0.57	-0.2	-0.6	-0.35	-0.23	0.71	0.67	-0.42	-0.7	-0.36	-0.34	-0.59	0.59	-0.49	-0.57		-0.68	-0.61	-0.41	-0.42	-0.59	0.49	-0.75	-0.74
Other Current Assets	0.96	0.3	0.93	0.57	0.95	0.85	-0.17	-0.83	-0.96	0.51	0.9	0.55	0.43	0.96	-0.63	0.96	0.93	-0.68		0.97	0.83	0.81	0.96	-0.41	0.92	0.95
Other Stockholder Equity	0.99	0.26	0.97	0.63	0.99	0.93	-0.33	-0.84	-0.99	0.55	0.9	0.63	0.5	0.99	-0.66	0.99	0.86	-0.61	0.97		0.84	0.91	0.99	-0.4	0.87	0.9
Total Liab	0.85	0.71	0.82	0.9	0.82	0.84	-0.33	-0.6	-0.82	0.47	0.76	0.53	0.41	0.85	-0.36	0.87	0.79	-0.41	0.83	0.84		0.77	0.85	0.14	0.71	0.75
Property Plant And Equipment Gross	0.93	0.17	0.91	0.68	0.93	0.96	-0.51	-0.8	-0.88	0.67	0.84	0.79	0.66	0.93	-0.52	0.91	0.64	-0.42	0.81	0.91	0.77		0.93	-0.3	0.71	0.73
Total Current Assets	1.0	0.25	0.99	0.66	1.0	0.94	-0.39	-0.86	-0.98	0.6	0.93	0.69	0.56	1.0	-0.61	0.98	0.83	-0.59	0.96	0.99	0.85	0.93		-0.38	0.83	0.86
Short Term Debt	-0.38	0.7	-0.38	0.42	-0.42	-0.23	-0.12	0.57	0.4	-0.26	-0.43	-0.26	-0.24	-0.38	0.57	-0.32	-0.31	0.49	-0.41	-0.4	0.14	-0.3	-0.38		-0.46	-0.42
Common Stock Total Equity	0.83	0.21	0.76	0.44	0.83	0.71	0.14	-0.78	-0.84	0.51	0.83	0.49	0.39	0.83	-0.74	0.83	0.86	-0.75	0.92	0.87	0.71	0.71	0.83	-0.46		0.99
Common Stock	0.86	0.28	0.8	0.47	0.85	0.75	0.04	-0.77	-0.87	0.48	0.83	0.47	0.36	0.86	-0.7	0.86	0.89	-0.74	0.95	0.9	0.75	0.73	0.86	-0.42	0.99

Click cells to compare fundamentals

Viridian Therapeutics Account Relationship Matchups

Viridian Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	30.3M	131.3M	203.7M	435.1M	490.4M	514.9M
Short Long Term Debt Total	8.3M	455K	520K	5.3M	21.0M	22.1M
Other Current Liab	100K	9.2M	10.5M	18.2M	23.3M	24.4M
Total Current Liabilities	10.2M	10.7M	13.6M	33.3M	26.6M	28.0M
Total Stockholder Equity	15.8M	120.0M	187.7M	395.1M	442.0M	464.1M
Property Plant And Equipment Net	523K	787K	2.1M	2.9M	3.3M	3.5M
Current Deferred Revenue	5.0M	301K	289K	288K	259.2K	246.2K
Net Debt	(16.5M)	(45.4M)	(41.8M)	(150.3M)	(81.8M)	(77.7M)
Retained Earnings	(168.2M)	(278.9M)	(358.3M)	(488.2M)	(725.9M)	(689.6M)
Accounts Payable	1.1M	670K	2.3M	14.2M	2.2M	2.1M
Cash	24.8M	45.9M	42.3M	155.6M	102.8M	108.0M
Non Current Assets Total	523K	1.6M	3.5M	10.5M	3.9M	2.6M
Non Currrent Assets Other	(523K)	857K	1.5M	7.6M	604K	1.0M
Cash And Short Term Investments	26.8M	127.6M	197.0M	424.6M	477.4M	501.2M
Net Receivables	24K	108K	451K	102K	91.8K	87.2K
Common Stock Shares Outstanding	2.1M	3.6M	11.9M	32.1M	44.8M	47.0M
Liabilities And Stockholders Equity	30.3M	131.3M	203.7M	435.1M	490.4M	514.9M
Non Current Liabilities Total	4.3M	544K	2.4M	6.7M	21.8M	22.9M
Other Current Assets	2.8M	2.0M	2.6M	6.5M	9.0M	9.5M
Other Stockholder Equity	183.6M	218.1M	412.1M	741.1M	960.5M	1.0B
Total Liab	14.5M	11.2M	16.0M	40.0M	48.4M	50.8M
Property Plant And Equipment Gross	523K	787K	3.8M	4.9M	4.4M	4.6M
Total Current Assets	29.7M	129.6M	200.2M	424.6M	486.5M	510.8M
Accumulated Other Comprehensive Income	(3.3M)	(8K)	(157K)	(390K)	338K	354.9K
Short Term Debt	4.0M	455K	520K	613K	843K	800.9K
Common Stock Total Equity	349K	42K	239K	414K	476.1K	499.9K
Common Stock	349K	42K	239K	414K	540K	567K
Net Tangible Assets	15.8M	(60.8M)	53.9M	252.9M	290.9M	305.4M
Property Plant Equipment	523K	787K	375K	1.3M	1.5M	774.1K
Net Invested Capital	24.1M	(60.8M)	53.9M	257.6M	255.7M	268.5M
Net Working Capital	19.6M	118.9M	186.5M	397.8M	459.8M	482.8M
Short Term Investments	2.0M	81.7M	154.7M	269.0M	374.5M	393.3M
Capital Stock	349K	180.8M	134.1M	142.6M	207.1M	122.0M

Pair Trading with Viridian Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viridian Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Viridian Stock

0.73	EWTX	Edgewise Therapeutics	Pair Corr
0.79	BHC	Bausch Health Companies	Pair Corr

Moving against Viridian Stock

0.62	INAB	In8bio Inc	Pair Corr
0.53	ELAN	Elanco Animal Health Potential Growth	Pair Corr
0.43	INMB	INmune Bio	Pair Corr
0.39	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.36	TAK	Takeda Pharmaceutical	Pair Corr

The ability to find closely correlated positions to Viridian Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viridian Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viridian Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viridian Therapeutics to buy it.

The correlation of Viridian Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viridian Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viridian Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Viridian Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Viridian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Viridian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Viridian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Viridian Therapeutics Stock:

How To Invest In Viridian

Details

Is Viridian Stock a good investment?

Details

What is Viridian Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.

You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.32)

Revenue Per Share

0.005

Quarterly Revenue Growth

0.194

Return On Assets

(0.32)

Return On Equity

(0.52)

The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Viridian Historical Balance Sheet

Viridian Therapeutics Inventory

(5.66 Million)

About Viridian Balance Sheet Analysis

Viridian Therapeutics Balance Sheet Chart

Total Current Liabilities

Viridian Therapeutics balance sheet Correlations

Viridian Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Viridian Therapeutics balance sheet Accounts

Pair Trading with Viridian Therapeutics

Moving together with Viridian Stock

Moving against Viridian Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Other Stockholder Equity	- 0.99	Retained Earnings
Total Current Assets	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Retained Earnings	- 0.98	Total Stockholder Equity
Retained Earnings	- 0.98	Other Current Liab